4th Feb 2008 17:00
AstraZeneca PLC04 February 2008 ASTRAZENECA BIOLOGICS DIVISION, MEDIMMUNE, SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR MOTAVIZUMAB AstraZeneca PLC announced today that its biologics division, MedImmune, hadsubmitted a Biologics License Application (BLA) to the U.S. Food & DrugAdministration (FDA) for motavizumab, an investigational monoclonal antibody(MAb) derived from recombinant DNA technology. "We expect that this submission will lead to the first new medicine delivered byMedImmune since we acquired the company in June 2007 and one of three newfilings that we plan to make this year. MedImmune has a well-establishedreputation in the prevention of RSV through its existing product, Synagis.Motavizumab offers the opportunity to build on this knowledge and improvetreatment for a young and vulnerable patient population," said David Brennan,Chief Executive Officer, AstraZeneca. 4 February 2008 Media Enquiries: Jamie Lacey, (MedImmune) +1 301 398 4035 Steve Brown, +44 207 304 5033 (24 hours) Edel McCaffrey, +44 207 304 5034 (24 hours) Investor Enquiries: Jonathan Hunt, +44 207 304 5087 Ed Seage, +1 302 886 4065 Karl Hard, +44 207 304 5322 Jorgen Winroth, +1 212 579 0506 Peter Vozzo, (MedImmune) +1 301 398 4358 - Ends - This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca